SBIR/STTR Research Award

Design And Development Of A Non-Invasive Non-Imaging Vascular Function Monitoring

Award identifier 958dd13f6fa99d1288cd3b418cb9e6bee4c77ffd295773d1029b337f045662b8Awarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$94,375

Program and phase

SBIR · Phase I

Award year

2008

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
Endothelix, Inc.
Proposal award date
Not reported
Contract end date
Not reported
UEI
G9TJEF3UJ663
Solicitation number
PHS2007-2
Topic code
Not reported

Research abstract

DESCRIPTION (provided by applicant): Cardiovascular disease (CVD) is the leading cause of death and the most expensive disease in the U.S. Many patients are asymptomatic before the first serious and often fatal event. Unlike cancers in which numerous under lying pathologies exist, the majority of CVD is caused by atherosclerosis. New solutions for early detection and treatment monitoring of atherosclerosis present major opportunities for prevention of CVD. In addition to saving lives, there is the potential for significant reductions in healthcare costs. It is widely accepted that endothelial dysfunction is the gateway to atherosclerosis. Opinion leaders have described endothelial function as the barometer of cardiovascular health [1]. Current methods of no ninvasive assessment of endothelial function are based on measuring arterial response to reactive hyperemia [31-33]. Endothelix, Inc. is developing a low-cost, non-invasive, non-imaging screening test for CVD (Digital Thermal Monitoring, DTM) based on meas uring fingertip thermal reactivity during the hyperemic response to brachial artery occlusion and release. The test involves the inflation of a blood pressure cuff on the arm for 2-5 minutes followed by immediate deflation, while monitoring temperature cha nges in the index fingers of the study and contralateral hands. Preliminary studies with an early prototype of the DTM device in two centers have shown that fingertip thermal reactivity is lower in patients with 1) known diagnosis of coronary heart disease , 2) extensive sub-clinical coronary atherosclerosis, and 3) high risk factors for atherosclerosis. Endothelix has received indications of a strong interest in the device after presentations at national cardiovascular conventions. The proposed VENDYS devic e will be suitable for more detailed investigations of this phenomenon at clinics, medical centers, and medical research facilities worldwide. Continued successful results from VENDYS studies and further refinement of the DTM technology can lead to eventua l large scale usage of the device including in outpatient clinics and ultimately for home-based monitoring. The specific aims of the proposed work are to 1) Develop a multi-channel DTM module that can measure fingertip temperatures during brachial artery o cclusion and release to an accuracy of 0.01xC. Success criteria are the demonstration of successful operation and performance of the software management of the DTM module, the cuff management (automated inflation and deflation) module, and the graphical us er interface for data entry, display and reporting of the test; and 2) Validate the performance of the integrated component modules through comparison with the existing prototype devices and repeatability testing. Success criteria are that the device perfo rm according to the design specifications when used by medical personnel with no specialized electronics or computer knowledge This grant application proposes to build a commercial version (VENDYSTM) of the early DTM prototype which can then be tested in l arge multi-center studies, particularly in pharmaceutical clinical trials and long term epidemiologic studies. Upon successful conclusion of these trials, the company intends to commercialize the device as a low-cost, non-invasive, non-imaging vascular str ess test. The company envisions that DTM technology would be incorporated in existing blood pressure devices as an affordable and easy-to-use tool for hospital and home based vascular health monitoring. PUBLIC HEALTH RELEVANCE: Widespread clinical evaluati on of endothelial dysfunction - an early and accurate indicator of cardiovascular disease - is currently hindered by the absence of an affordable, accurate, and non-invasive measurement technology. The proposed work seeks to refine and realize in a commerc ially viable product a novel technique of endothelial dysfunction assessment via the non-invasive, localized measurement of finger temperature during a cont

Technology keywords

Not reported

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.